Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Medical uses  





2 Pharmacology  





3 Manufacturing  





4 Clinical trials  





5 Authorizations  





6 See also  





7 References  














FAKHRAVAC






العربية
Català
Čeština
فارسی

Українська
Tiếng Vit
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 




In other projects  



Wikimedia Commons
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


FAKHRAVAC
A vial of FakhraVac
Vaccine description
TargetSARS-CoV-2
Vaccine typeInactivated
Clinical data
Other namesFakhra, MIVAC
Routes of
administration
Intramuscular
Legal status
Legal status
  • Emergency use authorization: IRN

FAKHRAVAC (Persian: واکسن فخرا) is a COVID-19 vaccine developed in Iran by the Organization of Defensive Innovation and Research,[1] a subsidiary of Iran's Ministry of Defense. It is the third Iranian COVID-19 vaccine reaching clinical trials.[1][2][3] It is currently in phase III.[4][5] It received emergency use authorization in Iran on 9 September 2021.[4]

The vaccine is named after the Iranian nuclear scientist Mohsen Fakhrizadeh.[1] According to the Iranian authorities, he was working on a vaccine in response to the COVID-19 pandemic in Iran.[1][6] Fakhrizadeh was assassinated in November 2020 in an attack Iran and US intelligence attributed to Israel.[1][7]

Medical uses[edit]

It requires two doses given by intramuscular injection 3 weeks apart.[5]

Pharmacology[edit]

FAKHRAVAC is an inactivated virus-based vaccine.[3]

Manufacturing[edit]

In August 2021, production capacity of the vaccine was reported to be 1 million dose per month and was planned to be "multiplied in a few months ".[4] In October 2021, the production was reported to be stopped amid Iran's growing vaccine imports.[8] In January 2022, the Director General of Health of the Ministry of Defense announced that the first shipment (around 462,000 doses) of the vaccine had been delivered to the Iranian Ministry of Health.[9]

Clinical trials[edit]

Clinical trials of FAKHRAVAC
Phase Registration number Start Number of participants Age of participants
Total Vaccine Control
I IRCT20210206050259N1 Archived 28 April 2021 at the Wayback Machine 8 March 2021 135 96? 39? (placebo) 18–55 years
II IRCT20210206050259N2 Archived 16 June 2021 at the Wayback Machine 8 June 2021 500 250 250 (placebo) 18–70 years
III IRCT20210206050259N3 Archived 7 September 2021 at the Wayback Machine 29 August 2021 41,128 20,564 20,564 (Sinopharm BIBP vaccine) >18 years

Authorizations[edit]

FAKHRAVAC received emergency use authorization in Iran on 9 September 2021.[4] In October 2021, Iran's Food and Drug Administration was considering giving full authorization to the vaccine for third/booster dose.[8]

See also[edit]

References[edit]

  1. ^ a b c d e Motamedi M (16 March 2021). "Iran starts human trials of its third domestic COVID vaccine". Al Jazeera.
  • ^ "Phase 1, safety, immunogenicity and dose finding for two strengths of 0.5 × 10^6 and 2.5 × 10^6 (TCID50) inactivated SARS-CoV-2 vaccine FAKHRAVAC (MIVAC) injected in two schedules of two doses, 2 and 3 weeks apart in healthy adults aged 18-55 years: a randomized, double blind, placebo controlled, clinical trial". en.irct.ir. Iran Registry of Clinical Trials. Retrieved 21 March 2021.
  • ^ a b "Phase 2 trial of safety and immunogenicity of 10 micro gram inactivated SARS-CoV-2 vaccine (FAKHRAVAC), two doses two weeks apart in adults aged 18-70 years: a randomized, double-blind, placebo-controlled, clinical trial". en.irct.ir. Iran Registry of Clinical Trials. Retrieved 15 June 2021.
  • ^ a b c d "Iran Authorizes Emergency Use of Third Homegrown Vaccine - Defense news". Tasnim News Agency. Retrieved 9 September 2021.
  • ^ a b "IRCT | Comparison of the safety, efficacy and immunogenicity of Fakhravac and Sinopharm SARS-CoV-2 vaccines, in adults aged 18 and over; a phase III randomised, non-inferiority clinical trial". en.irct.ir. Archived from the original on 7 September 2021. Retrieved 7 September 2021.
  • ^ "Research center run by Fakhrizadeh produced first COVID-19 test kits for Iranians: Defense minister". Pars Today. 28 November 2020. Archived from the original on 5 December 2020. Retrieved 7 September 2021.
  • ^ The Assassination of Fakhrizadeh: Considerations and Consequences
  • ^ a b Sinaee, Maryam (19 October 2021). "Iran Defense Ministry's Covid Vaccine Production To Be Discontinued". Iran International. Retrieved 24 October 2021.
  • ^ "تحویل نخستین محموله واکسن فخرا به وزارت بهداشت". YJC News. 19 January 2022.
  • icon Viruses
  • virus icon COVID-19

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=FAKHRAVAC&oldid=1215798672"

    Categories: 
    Iranian COVID-19 vaccines
    Science and technology in Iran
    Inactivated vaccines
    Hidden categories: 
    Articles with short description
    Short description is different from Wikidata
    Use dmy dates from June 2021
    Drugs with non-standard legal status
    Chemical articles without CAS registry number
    Articles without EBI source
    Chemical pages without ChemSpiderID
    Chemical pages without DrugBank identifier
    Articles without KEGG source
    Articles without InChI source
    Articles without UNII source
    Drugs missing an ATC code
    Articles containing unverified chemical infoboxes
    Drugs that are a vaccine
    Articles containing Persian-language text
    Webarchive template wayback links
     



    This page was last edited on 27 March 2024, at 05:29 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki